Michael E. Menefee

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study

Keith C. Bible, Vera J. Suman, Julian R. Molina et al. · The Lancet Oncology · 2010 · 416 citations · Full text

Medicine, Oncology, Pharmacology +8

A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer

Keith C. Bible, Vera J. Suman, Michael E. Menefee et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 176 citations · Full text

Medicine, Oncology, Pharmacology +15

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial

Maria E. Cabanillas, Jonas A. de Souza, Susan M. Geyer et al. · Journal of Clinical Oncology · 2017 · 130 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H

Keith C. Bible, Vera J. Suman, Julian R. Molina et al. · The Journal of Clinical Endocrinology & Metabolism · 2014 · 118 citations · Full text

Medicine, Oncology, Pharmacology +16

Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial

Robert C. Smallridge, John A. Copland, Marcia S. Brose et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 114 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16